A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
about
Current challenges and novel treatment strategies in double hit lymphomasNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyThe development of immunoconjugates for targeted cancer therapyNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewBuilding better monoclonal antibody-based therapeutics.Antibody Drug Conjugates: Nonclinical Safety Considerations.Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical TrialsAntibody therapy for pediatric leukemia.Current status of antibody therapy in ALL.Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development.Chemotherapy-free treatment in patients with follicular lymphoma.Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.Emerging immunological drugs for chronic lymphocytic leukemia.Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.Emerging antibody-drug conjugates for treating lymphoid malignancies.Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates.Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Obinutuzumab for the treatment of indolent lymphomaA novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay.Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.The landscape of new drugs in lymphomaAntibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.DNA damaging agent-based antibody-drug conjugates for cancer therapy
P2860
Q26770385-CBB74F01-EF72-43E9-BD25-A58A619A971EQ26782270-8AF86371-2289-490F-AE0D-A76981B4E65DQ27021990-4C9BF03A-DCAD-4A22-BC7D-B0294F656614Q27304386-A20533AB-C867-49B9-B657-0D148B0A4E6CQ35817552-89CD6035-99B4-4259-AEBD-BCDE6227DD7EQ35967917-6C01DBD1-6CEC-445E-B6EE-4382A6C2E991Q36366709-0EBCE82D-6B6B-425A-A41C-EAC3B4196171Q37725578-F6730E45-0006-4337-BAD8-87C04FABB12DQ38266338-81B4D3AA-A604-4F4A-ABFF-7CFAFC74A042Q38282458-F36D789F-0DA9-4054-85A0-CE19B0385986Q38317235-D50372BA-A00B-44A1-B8E8-21206B6FCCA1Q38434473-DCF92508-5F04-499A-BB61-ADB2A769ECFEQ38543771-EF3200AA-AEF9-4752-B3CF-E77159DE17EFQ38550992-92B405AF-3FC8-4167-9F29-6E020F8ED244Q38579129-50AA1E2F-923F-49E7-9585-E3D0ED7E9243Q38632313-3CE6C999-2783-4D32-9C3E-0674B9D138EBQ38707852-F6E9418D-766F-4E29-9FE2-EC51B4790653Q38764062-F619AE97-CB54-4964-BA4D-F5F86BA01F8EQ38798481-D56D6040-5F9D-4738-AB6B-1607E6C3AA5DQ38803361-C98A3D63-2BC7-45BE-B378-10EB8FA08DF2Q38818380-4B3A0DE9-74B9-4D80-8EF3-40DB0F1BD79CQ38845355-0C43CE29-5763-4E73-AB26-5FB3EE9CD37AQ38896683-139115B2-93FA-4C32-9BC8-C2D9AEEEA13CQ38915595-C78974B8-F024-4F8E-83DA-F6A877D6BEABQ38932868-06467504-F552-4E31-ACC4-E25EF8F66816Q39061630-F650DE96-AA28-4159-AAAB-2182F3F418CAQ39210427-8900C4E3-A91F-49F2-96A9-E38B12E9AAD5Q39381251-3FD998B1-867F-4788-8373-A127EB7B89FFQ40835274-B832045C-BD83-458A-BB84-52328F08A614Q40971388-DC921E0F-605F-423F-8E37-A53702567081Q48192887-96287ADB-5837-4E0A-B360-8F2BDF6B778DQ49999453-78F4F703-BFF0-49B3-B16C-5AC1775C1D0DQ53033031-504C15D8-D92A-486A-B7F9-52D59E5A5650Q57192403-57CD9789-9C03-449D-8012-BA3BB72A3D65
P2860
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A dose-escalation study of SAR ...... y B-cell non-Hodgkin lymphoma.
@en
A dose-escalation study of SAR ...... y B-cell non-Hodgkin lymphoma.
@nl
type
label
A dose-escalation study of SAR ...... y B-cell non-Hodgkin lymphoma.
@en
A dose-escalation study of SAR ...... y B-cell non-Hodgkin lymphoma.
@nl
prefLabel
A dose-escalation study of SAR ...... y B-cell non-Hodgkin lymphoma.
@en
A dose-escalation study of SAR ...... y B-cell non-Hodgkin lymphoma.
@nl
P2093
P1476
A dose-escalation study of SAR ...... ry B-cell non-Hodgkin lymphoma
@en
P2093
Andrea Varga
Anne Caron
Bertrand Coiffier
Christiane Copie
Fabrice Laine
Franck Morschhauser
Herve Tilly
Jehan Dupuis
John Lambert
Laurence Hatteville
P304
P356
10.1158/1078-0432.CCR-13-0580
P407
P577
2013-10-16T00:00:00Z